#United States #Woburn #George Quinoy #Micro Medical Solutions #MicroStent

Leadership Transformation at Micro Medical Solutions

Micro Medical Solutions (MMS), a leader in developing minimally invasive vascular solutions for treating Critical Limb Ischemia (CLI), has officially announced the appointment of George Quinoy as President and Chief Executive Officer. This key transition heralds a new chapter for the company as it aims to expedite commercialization and create substantial value for patients and stakeholders alike.

Transitioning Leadership Roles

In this strategic reshuffle, MMS founder Greg Sullivan will step into the role of Chief Technology Officer. Sullivan focuses on advancing the company's technology platform, spearheading next-generation product development, and overseeing clinical evidence initiatives. As Quinoy joins the leadership team, he will maintain a seat on the MMS Board of Directors, ensuring a seamless transition and strategic continuity.

The leadership change comes at a crucial time as MMS approaches pivotal milestones, including seeking FDA approval for its flagship product, the MicroStent™. Sullivan expressed confidence in Quinoy’s capabilities, stating, “George is an exceptional leader with a proven track record of scaling high-growth medical device companies.” This transition is expected to enhance MMS’s operational efficiency and bolster value creation across all levels.

Quinoy’s Background and Vision

Bringing over 20 years of extensive experience in the vascular and medical device sectors, Quinoy is well-prepared to lead MMS. His illustrious career includes senior leadership positions at major firms such as AVE, Medtronic, and Volcano Corporation. His background encompasses not only commercialization strategies but also fostering strategic partnerships and building scalable business models, resulting in significant acquisitions and shareholder gains.

At MMS, Quinoy aims to:

• - Propel commercial readiness and develop a robust global go-to-market strategy
• - Expand strategic partnerships to drive market adoption
• - Construct a scalable infrastructure for swift market penetration post-FDA approval

Quinoy remarked, “This is a pivotal moment for MMS. With compelling trial data, a completed PMA submission, and increasing interest from strategic partners, we are positioned to revolutionize the treatment of CLI.” His vision emphasizes that MMS is primed for growth and innovation, aiming to make a substantial impact in the medical field.

Current Developments and Future Aspirations

MMS is navigating an important inflection point with several key developments including:

• - Ongoing PMA submission that is moving towards FDA approval
• - Compelling evidence from clinical trials supporting the efficacy of the MicroStent™ in redefining CLI treatment protocols
• - Growing strategic interest from partners, signaling robust commercial potential

This leadership reorganization not only enhances MMS's capacity to capitalize on immediate market opportunities but also reinforces the company’s long-term commitment to innovation. As it stands, MMS is on a promising path towards becoming a strategic asset in the vascular treatment sector.

About Micro Medical Solutions

Micro Medical Solutions is at the forefront of transforming vascular care through minimally invasive technologies. Their groundbreaking product, the MicroStent™, addresses intricate below-the-knee vascular diseases and aims to significantly mitigate the risks of limb amputation. With FDA approval on the horizon and plans for global commercialization being set in motion, the company is committed to improving outcomes for patients suffering from Critical Limb Ischemia. For further details, visit www.micromedicalsolutions.com.